<DOC>
	<DOCNO>NCT01878786</DOCNO>
	<brief_summary>The purpose pilot study evaluate concentration-controlled everolimus low dose tacrolimus compare early conversion CNI-free regimen MMF/MPA standard dose tacrolimus de novo renal transplant recipient ECD/DCD kidney . Given tacrolimus MMF/MPA widely prescribe immunosuppressive regimen United States , comparison tacrolimus MMF/MPA regimens investigational therapy treatment regimens need . Also , consider fact ECD/DCD fast grow fraction donor , evaluation various regimen ' effect rather delicate ECD/DCD kidney necessary .</brief_summary>
	<brief_title>A Pilot Study Comparing Safety Efficacy Everolimus With Other Medicines Recipients ECD/DCD Kidneys</brief_title>
	<detailed_description>The purpose pilot study evaluate concentration-controlled everolimus low dose tacrolimus compare early conversion CNI-free regimen MMF/MPA standard dose tacrolimus de novo renal transplant recipient ECD/DCD kidney . Given tacrolimus MMF/MPA widely prescribe immunosuppressive regimen United States , comparison tacrolimus MMF/MPA regimens investigational therapy treatment regimens need . Also , consider fact ECD/DCD fast grow fraction donor , evaluation various regimen ' effect rather delicate ECD/DCD kidney necessary . The primary objective study evaluate concentration-controlled everolimus low dose tacrolimus compare MMF/MPA standard dose tacrolimus 24 month post-transplant respect composite efficacy failure rate ( treat biopsy proven acute rejection episode ( BPAR ) , graft loss , death , loss follow-up ) de novo renal transplant recipient . The key secondary objective compare renal function everolimus treatment arm MMF/MPA treatment arm 12 24 month post-transplantation . Renal function measure calculated glomerular filtration rate ( GFR ) , use MDRD ( Modification Diet Renal Disease ) formula ( 20 ) .</detailed_description>
	<mesh_term>Delayed Graft Function</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Male female recipient 1865 year age undergoing primary secondary kidney transplantation Recipients primary secondary cadaveric , ECD/DCD kidney ( define follow ) Donor whose heart irreversibly stop beat , previously refer nonheartbeating asystolic donation Braindead donor &gt; 60 year old Donor age 5059 year old two follow criterion : History hypertension Terminal serum creatinine ≥ 1.5 mg/dL Death result cerebrovascular accident Patients give write informed consent participate study Cold ischemic time ( CIT ) &gt; 30 hour Patients ABO incompatible transplant , T , B cell crossmatch positive transplant Patients know hypersensitivity study drug drug similar chemical class Noncontrolled DCD Donor age &gt; 70 Patients BMI &gt; 32 baseline surgery Pregnant lactating female Females childbearing potential unwilling use effective mean contraception plan become pregnant Patients platelet count &lt; 100,000/mm3 evaluation randomization . Patients absolute neutrophil count &lt; 1,500/mm³ baseline surgery white blood cell count &lt; 4,500/mm³ Patients recipient multiple solid organ transplant Patients severe hypercholesterolemia ( &gt; 350 mg/dL ; &gt; 9 mmol/L ) hypertriglyceridemia ( &gt; 500 mg/dL ; &gt; 5.6 mmol/L ) . Patients control hyperlipidemia acceptable Patients abnormal liver profile ALT , AST , Alk Phos total bilirubin &gt; 3 time upper normal limit Patients treat drug strong inducer inhibitor cytochrome P450 3A4 , terfenadine , astemizole , cisapride , erythromycin , azithromycin , itraconazole , rifampin lovastatin Patients receive investigational drug treat nonprotocol immunosuppressive drug treatment within 30 day 5 halflives prior randomization Patients history malignancy organ system , treat untreated , within past 2 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin Patients HIVpositive Hepatitis C ( PCR+ ) B surface antigen positive Recipients organs donor test positive Hepatitis B surface antigen Hepatitis C ( PCR+ ) exclude Patients history severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus ( Hgb A1c &lt; 7.0 % ) baseline Patients surgical medical condition , opinion investigator , might significantly alter absorption , distribution , metabolism excretion study medication , and/or presence severe diarrhea active peptic ulcer Patients cardiac failure ( e.g . rest dyspnea , symptom less ordinary activity , mark limitation activity ) time screen severe cardiac disease determine investigator Patients abnormal physical laboratory finding clinical significance within 3 month randomization would interfere objective study Patients history coagulopathy medical condition require longterm anticoagulation therapy transplantation ( Low dose aspirin treatment allow ) Patients known history focal segmental glomeruloscrelosis Presence psychiatric illness ( i.e. , schizophrenia , bipolar , major depression ) , opinion investigator , would interfere study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>kidney failure</keyword>
</DOC>